Jacobio Pharma repurchases 80.70 thousand shares at average HK$5.62; treasury stock climbs to 7.07 million

Bulletin Express05-14

Jacobio Pharmaceuticals Group Co., Ltd. disclosed a share buy-back executed on 14 May 2026 under its Hong Kong mandate dated 10 June 2025. The company repurchased 80,700 ordinary shares on the Stock Exchange at prices ranging from HK$5.60 to HK$5.63, translating into a volume-weighted average cost of HK$5.62 per share and an aggregate consideration of HK$0.45 million.

Following the transaction, Jacobio’s issued share capital (excluding treasury shares) declined marginally to 784.69 million shares, a 0.0103% reduction from the previous balance of 784.77 million shares. Treasury shares increased to 7.07 million, while total issued shares remained unchanged at 791.76 million.

Since receiving the 10 June 2025 shareholder authorisation permitting the repurchase of up to 78.87 million shares, the company has bought back 4.05 million shares, representing 0.51% of the shares outstanding on the mandate date. All repurchased shares to date have been retained as treasury stock.

Under Main Board Rule 10.06(3)(a), Jacobio is subject to a moratorium on issuing new shares or disposing of treasury shares until 13 June 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1151927228?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-14 18:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151927228","market":"hk","top_or_hot":-1,"title":"Jacobio Pharma repurchases 80.70 thousand shares at average HK$5.62; treasury stock climbs to 7.07 million","media":"Bulletin Express","content":"<p>Jacobio Pharmaceuticals Group Co., Ltd. disclosed a share buy-back executed on 14 May 2026 under its Hong Kong mandate dated 10 June 2025. The company repurchased 80,700 ordinary shares on the Stock Exchange at prices ranging from HK$5.60 to HK$5.63, translating into a volume-weighted average cost of HK$5.62 per share and an aggregate consideration of HK$0.45 million.</p>\n<p>Following the transaction, Jacobio’s issued share capital (excluding treasury shares) declined marginally to 784.69 million shares, a 0.0103% reduction from the previous balance of 784.77 million shares. Treasury shares increased to 7.07 million, while total issued shares remained unchanged at 791.76 million.</p>\n<p>Since receiving the 10 June 2025 shareholder authorisation permitting the repurchase of up to 78.87 million shares, the company has bought back 4.05 million shares, representing 0.51% of the shares outstanding on the mandate date. All repurchased shares to date have been retained as treasury stock.</p>\n<p>Under Main Board Rule 10.06(3)(a), Jacobio is subject to a moratorium on issuing new shares or disposing of treasury shares until 13 June 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jacobio Pharma repurchases 80.70 thousand shares at average HK$5.62; treasury stock climbs to 7.07 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJacobio Pharma repurchases 80.70 thousand shares at average HK$5.62; treasury stock climbs to 7.07 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-14 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jacobio Pharmaceuticals Group Co., Ltd. disclosed a share buy-back executed on 14 May 2026 under its Hong Kong mandate dated 10 June 2025. The company repurchased 80,700 ordinary shares on the Stock Exchange at prices ranging from HK$5.60 to HK$5.63, translating into a volume-weighted average cost of HK$5.62 per share and an aggregate consideration of HK$0.45 million.</p>\n<p>Following the transaction, Jacobio’s issued share capital (excluding treasury shares) declined marginally to 784.69 million shares, a 0.0103% reduction from the previous balance of 784.77 million shares. Treasury shares increased to 7.07 million, while total issued shares remained unchanged at 791.76 million.</p>\n<p>Since receiving the 10 June 2025 shareholder authorisation permitting the repurchase of up to 78.87 million shares, the company has bought back 4.05 million shares, representing 0.51% of the shares outstanding on the mandate date. All repurchased shares to date have been retained as treasury stock.</p>\n<p>Under Main Board Rule 10.06(3)(a), Jacobio is subject to a moratorium on issuing new shares or disposing of treasury shares until 13 June 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01167","symbol_name":"加科思-B","start_time":0,"source_url":"","article_id":"1151927228","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151927228","pubTimestamp":1778754169,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Jacobio Pharmaceuticals Group Co., Ltd. disclosed a share buy-back executed on 14 May 2026 under its Hong Kong mandate dated 10 June 2025. The company repurchased 80,700 ordinary shares on the Stock...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01167":"加科思-B"},"translate_title":"雅可比奥制药回购8.07万股，均价5.62港元；库存股攀升至707万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01167":1},"content_text":"Jacobio Pharmaceuticals Group Co., Ltd. disclosed a share buy-back executed on 14 May 2026 under its Hong Kong mandate dated 10 June 2025. The company repurchased 80,700 ordinary shares on the Stock Exchange at prices ranging from HK$5.60 to HK$5.63, translating into a volume-weighted average cost of HK$5.62 per share and an aggregate consideration of HK$0.45 million.\nFollowing the transaction, Jacobio’s issued share capital (excluding treasury shares) declined marginally to 784.69 million shares, a 0.0103% reduction from the previous balance of 784.77 million shares. Treasury shares increased to 7.07 million, while total issued shares remained unchanged at 791.76 million.\nSince receiving the 10 June 2025 shareholder authorisation permitting the repurchase of up to 78.87 million shares, the company has bought back 4.05 million shares, representing 0.51% of the shares outstanding on the mandate date. All repurchased shares to date have been retained as treasury stock.\nUnder Main Board Rule 10.06(3)(a), Jacobio is subject to a moratorium on issuing new shares or disposing of treasury shares until 13 June 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1151927228","isCrawlerRequest":true}